Tesamorelin began with a basic question: how does the brain tell the body to make growth hormone?
The hormone behind the hormone
In the 1950s and 60s, scientists realized the brain’s hypothalamus controls the pituitary gland by sending chemical signals. Roger Guillemin and Andrew Schally raced to identify them, work that earned them a Nobel Prize in 1977. The signal that triggers growth hormone proved elusive for years.
In 1982, two teams, including Guillemin’s, finally pinned it down. They found it in an unlikely place: tumors in patients with acromegaly, a condition of excess growth hormone. The tumors were pumping out the very signal scientists had been hunting. It was named growth hormone-releasing hormone, or GHRH.
A good molecule with a flaw
Natural GHRH was a promising medicine, since it nudges the body to make its own growth hormone rather than replacing it. But it had a big drawback. The body destroys it within minutes, so it was impractical as a drug.
Researchers spent years tweaking the molecule. The key breakthrough was attaching a small chemical group to one end of the GHRH chain. This tiny addition shielded it from the enzymes that normally chew it up, so it lasted long enough to work. The result was tesamorelin.
A medical problem in search of a solution
Meanwhile, a different story was unfolding. In the mid-1990s, new HIV drugs turned the disease from a death sentence into a manageable condition. But many long-term patients developed an unexpected side effect called lipodystrophy: fat built up deep in the abdomen around the organs, while fat in the face and limbs thinned out. This belly fat wasn’t just cosmetic. It raised heart disease risk, and diet and exercise often didn’t budge it.
Researchers noticed that growth hormone helps burn this kind of fat, but giving patients growth hormone directly came with side effects, such as swelling and effects on blood sugar. Tesamorelin offered a gentler route: prompting the body to release its own growth hormone in natural pulses.
From lab to pharmacy
A Montreal company, Theratechnologies, took up the effort. Large clinical trials, with leading researchers like Julian Falutz and Steven Grinspoon, tested daily injections in people with HIV and excess belly fat. A major 2007 study in The New England Journal of Medicine found that tesamorelin significantly reduced deep abdominal fat compared with placebo.
In November 2010, the U.S. FDA approved tesamorelin, sold under the brand name Egrifta, for reducing excess abdominal fat in HIV patients with lipodystrophy. It remains the only treatment approved for that purpose. The formulation was later improved to make it more convenient for patients.
What it is and isn’t
Tesamorelin is approved for a specific group of patients, not as a general weight-loss drug. Its popularity has grown beyond that group, with some people seeking it for anti-aging or body composition goals. Those uses are not approved, and the long-term effects in healthy people haven’t been well studied. Anyone considering it should talk to a doctor.
The takeaway
Tesamorelin took about three decades to arrive: a hormone found in tumors, a clever chemical fix, and a medical need that appeared at just the right time. It’s a good example of how basic curiosity about how the body works can eventually become a treatment for people who need it.
This article is for general information and is not medical advice.
